TY - JOUR
T1 - Simultaneous electrical detection of IL-6 and PCT using a microfluidic biochip platform
AU - Berger, Jacob
AU - Valera, Enrique
AU - Jankelow, Aaron
AU - Garcia, Carlos
AU - Akhand, Manik
AU - Heredia, John
AU - Ghonge, Tanmay
AU - Liu, Cynthia
AU - Font-Bartumeus, Victor
AU - Oshana, Gina
AU - Tiao, Justin
AU - Bashir, Rashid
N1 - Funding Information:
The authors thank A. Hasnain, V. Kindratenko, M. Saadah, and A. Bobat for their help on devices fabrication. The authors acknowledge the support of Center for Integration of Medicine and Innovative Technology Innovation (CIMIT)‘s Point-of-Care Technology Center in Primary Care (POCTRN) Grant, the support of NIH (project number 1 R21 AI146865 A), and funding from University of Illinois at Urbana-Champaign.
PY - 2020/6/1
Y1 - 2020/6/1
N2 - Sepsis, a life-threatening organ dysfunction caused by a dysregulated host response, leads the U.S in both mortality rate and cost of treatment. Sepsis treatment protocols currently rely on broad and non-specific parameters like heart and respiration rate, and temperature; however, studies show that biomarkers Interlukin-6 (IL-6) and Procalcitonin (PCT) correlate to sepsis progression and response to treatment. Prior work also suggests that using multi-parameter predictive analytics with biomarkers and clinical information can inform treatment to improve outcome. A point-of-care (POC) platform that provides information for multiple biomarkers can aid in the diagnosis and prognosis of potentially septic patients. Using impedance cytometry, microbead immunoassays, and biotin-streptavidin binding, we report a microfluidic POC system that correlates microbead capture to IL-6 and PCT concentrations. A multiplexed microbead immunoassay is developed and validated for simultaneous detection of both IL-6 and PCT from human plasma samples. Using the POC platform, we quantified plasma samples containing healthy, medium (~103pg/ml) and high (~105pg/ml) IL-6 and PCT concentrations with various levels of significance (P < 0.05-P < 0.00001) and validated the concept of this device as a POC platform for sepsis biomarkers.
AB - Sepsis, a life-threatening organ dysfunction caused by a dysregulated host response, leads the U.S in both mortality rate and cost of treatment. Sepsis treatment protocols currently rely on broad and non-specific parameters like heart and respiration rate, and temperature; however, studies show that biomarkers Interlukin-6 (IL-6) and Procalcitonin (PCT) correlate to sepsis progression and response to treatment. Prior work also suggests that using multi-parameter predictive analytics with biomarkers and clinical information can inform treatment to improve outcome. A point-of-care (POC) platform that provides information for multiple biomarkers can aid in the diagnosis and prognosis of potentially septic patients. Using impedance cytometry, microbead immunoassays, and biotin-streptavidin binding, we report a microfluidic POC system that correlates microbead capture to IL-6 and PCT concentrations. A multiplexed microbead immunoassay is developed and validated for simultaneous detection of both IL-6 and PCT from human plasma samples. Using the POC platform, we quantified plasma samples containing healthy, medium (~103pg/ml) and high (~105pg/ml) IL-6 and PCT concentrations with various levels of significance (P < 0.05-P < 0.00001) and validated the concept of this device as a POC platform for sepsis biomarkers.
KW - IL-6 and PCT
KW - Micro-bead assay
KW - Microfluidic electrical impedance
KW - Point-of-care diagnostics
KW - Protein detection
KW - Sepsis
UR - http://www.scopus.com/inward/record.url?scp=85084871632&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084871632&partnerID=8YFLogxK
U2 - 10.1007/s10544-020-00492-6
DO - 10.1007/s10544-020-00492-6
M3 - Article
C2 - 32419087
AN - SCOPUS:85084871632
VL - 22
JO - Biomedical Microdevices
JF - Biomedical Microdevices
SN - 1387-2176
IS - 2
M1 - 36
ER -